Tyra Bioscience(TYRA)
$19.61+0.04 (+0.20%)
TYRA
Tyra Bioscience financials statements
$19.61
At close:+0.04 (+0.20%)
Want to see TYRA full AI Analyst Report?
Tyra Bioscience (TYRA) Ratios
159 Followers
Tyra Bioscience Ratios
TYRA's free cash flow for Q3 2026 was $-32.30M. For the 2026 fiscal year, TYRA's free cash flow was decreased by $-90.00K and operating cash flow was $-32.21M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 14.67 | 23.81 | 13.80 | 45.13 | 84.09 |
| Quick Ratio | 14.67 | 23.81 | 13.80 | 45.13 | 84.09 |
| Cash Ratio | 4.28 | 6.30 | 3.78 | 44.06 | 83.57 |
| Solvency Ratio | -5.10 | -4.21 | -3.18 | -6.59 | -5.27 |
| Operating Cash Flow Ratio | -5.26 | -4.78 | -3.27 | -8.82 | -6.57 |
| Short-Term Operating Cash Flow Coverage | -201.57 | -169.35 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 242.02M | $ 327.06M | $ 190.08M | $ 248.94M | $ 299.09M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.02 | 0.03 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.02 | 0.02 | 0.03 | 0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.02 | 0.02 | 0.03 | 0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.09 | 1.06 | 1.11 | 1.03 | 1.02 |
| Debt Service Coverage Ratio | -252.97 | -208.65 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.10 | 0.11 | 0.15 | 0.06 | 0.03 |
| Net Debt to EBITDA | 0.60 | 1.00 | 0.65 | 4.24 | 11.51 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 90.35% | 83.01% | 86.48% | 93.89% | 100.02% |
| Return on Assets (ROA) | -42.44% | -23.79% | -30.61% | -20.78% | -8.57% |
| Return on Equity (ROE) | -46.28% | -25.20% | -33.85% | -21.46% | -8.71% |
| Return on Capital Employed (ROCE) | -50.19% | -29.85% | -37.97% | -22.62% | -8.67% |
| Return on Invested Capital (ROIC) | -50.10% | -29.82% | -37.92% | -22.61% | -8.67% |
| Return on Tangible Assets | -42.44% | -23.79% | -30.61% | -20.78% | -8.57% |
| Earnings Yield | -7.65% | -10.87% | -11.69% | -17.38% | -4.51% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.60 | -1.22 | -1.17 | -1.20 | -0.57 |
| Free Cash Flow Per Share | -1.60 | -1.23 | -1.19 | -1.21 | -0.59 |
| Dividend Paid and CapEx Coverage Ratio | -674.77 | -105.08 | -65.12 | -89.96 | -35.92 |
| Capital Expenditure Coverage Ratio | -674.77 | -105.08 | -65.12 | -89.96 | -35.92 |
| Operating Cash Flow Coverage Ratio | -16.38 | -11.21 | -7.72 | -19.18 | -20.07 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -6.08% | -8.86% | -8.61% | -15.97% | -4.19% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -13.08 | -9.21 | -8.56 | -5.75 | -22.18 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 6.05 | 2.32 | 2.90 | 1.23 | 1.93 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -16.45 | -11.29 | -11.62 | -6.26 | -23.89 |
| Price-to-Operating Cash Flow Ratio | -16.47 | -11.40 | -11.80 | -6.33 | -24.56 |
| Price-to-Earnings Growth (PEG) Ratio | -0.40 | 1.36 | -0.27 | -0.06 | -0.12 |
| Enterprise Value Multiple | -12.52 | -8.25 | -6.78 | -1.19 | -10.79 |
| Enterprise Value | 1.50B | 709.58M | 539.94M | 69.73M | 282.08M |
| EV to EBITDA | -12.52 | -8.25 | -6.78 | -1.19 | -10.79 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -15.69 | -10.07 | -10.61 | -1.37 | -11.56 |
| EV to Operating Cash Flow | -15.72 | -10.17 | -10.77 | -1.39 | -11.88 |
| Tangible Book Value Per Share | 4.35 | 6.00 | 4.78 | 6.16 | 7.28 |
| Shareholders’ Equity Per Share | 4.35 | 6.00 | 4.78 | 6.16 | 7.28 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.01 | -1.51 | -1.62 | -1.32 | -0.63 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.86 | 0.94 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.79 | 0.81 | 0.73 | 0.91 | 0.90 |
Currency in USD

